Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Anthony R Mato,Lindsey E Roeker,Nicole Lamanna,John N Allan,Lori Leslie,John M Pagel,Krish Patel,Anders Osterborg,Daniel Wojenski,Manali Kamdar,Scott F Huntington,Matthew S Davids,Jennifer R Brown,Darko Antic,Ryan Jacobs,Inhye E Ahn,Jeffrey Pu,Krista M Isaac,Paul M Barr,Chaitra S Ujjani,Mark B Geyer,Ellin Berman,Andrew D Zelenetz,Nikita Malakhov,Richard R Furman,Michael Koropsak,Neil Bailey,Lotta Hanson,Guilherme F Perini,Shuo Ma,Christine E Ryan,Adrian Wiestner,Craig A Portell,Mazyar Shadman,Elise A Chong,Danielle M Brander,Suchitra Sundaram,Amanda N Seddon,Erlene Seymour,Meera Patel,Nicolas Martinez-Calle,Talha Munir,Renata Walewska,Angus Broom,Harriet Walter,Dima El-Sharkawi,Helen Parry,Matthew R Wilson,Piers E M Patten,José-Ángel Hernández-Rivas,Fatima Miras,Noemi Fernández Escalada,Paola Ghione,Chadi Nabhan,Sonia Lebowitz,Erica Bhavsar,Javier López-Jiménez,Daniel Naya,Jose Antonio Garcia-Marco,Sigrid S Skånland,Raul Cordoba,Toby A Eyre
DOI: https://doi.org/10.1182/blood.2020006965
IF: 20.3
2020-09-03
Blood
Abstract:Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection and poor outcomes related to coronavirus disease 2019 (COVID-19). Robust analysis of outcomes for CLL patients, particularly examining effects of baseline characteristics and CLL-directed therapy, is critical to optimally manage CLL patients through this evolving pandemic. CLL patients diagnosed with symptomatic COVID-19 across 43 international centers (n = 198) were included. Hospital admission occurred in 90%. Median age at COVID-19 diagnosis was 70.5 years. Median Cumulative Illness Rating Scale score was 8 (range, 4-32). Thirty-nine percent were treatment naive ("watch and wait"), while 61% had received ≥1 CLL-directed therapy (median, 2; range, 1-8). Ninety patients (45%) were receiving active CLL therapy at COVID-19 diagnosis, most commonly Bruton tyrosine kinase inhibitors (BTKi's; n = 68/90 [76%]). At a median follow-up of 16 days, the overall case fatality rate was 33%, though 25% remain admitted. Watch-and-wait and treated cohorts had similar rates of admission (89% vs 90%), intensive care unit admission (35% vs 36%), intubation (33% vs 25%), and mortality (37% vs 32%). CLL-directed treatment with BTKi's at COVID-19 diagnosis did not impact survival (case fatality rate, 34% vs 35%), though the BTKi was held during the COVID-19 course for most patients. These data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death. Future epidemiologic studies are needed to assess severe acute respiratory syndrome coronavirus 2 infection risk, these data should be validated independently, and randomized studies of BTKi's in COVID-19 are needed to provide definitive evidence of benefit.